International Journal of Rheumatic Diseases最新文献

{"title":"Serum Biomarkers and Musculoskeletal Ultrasound for Assessment of Disease Activity in Patients With Juvenile Idiopathic Arthritis During Tocilizumab Therapy","authors":"Ehsan Khalifa Elsayed, Mervat Abd El Satar El Sergany, Marwa Ahmed Aboelhawa, Nivin Naeem Mohammad Baiomy, Amal Mohamad El-Barbary","doi":"10.1111/1756-185X.70007","DOIUrl":"10.1111/1756-185X.70007","url":null,"abstract":"<p>Polyarticular JIA (p-JIA), as defined by ILAR, refers to arthritis involving five or more joints within the first 6 months of the disease. This subgroup is further classified into two categories: rheumatoid factor (RF) positive or RF negative. The RF-positive category refers to individuals who have tested positive for RF on two or more tests, with at least 3 months between each test, within the first 6 months [<span>1</span>].</p><p>Given the growing prevalence of Polyarticular JIA (p-JIA) treatment, TCZ has emerged as a primary biologic agent [<span>2</span>]. Consequently, there is a rising demand for an innovative and reliable biomarker that can be utilized for the detection and monitoring of disease activity while undergoing IL-6 blockade therapy. TCZ has demonstrated the ability to impede IL-6R signaling, resulting in a rapid decrease in C-reactive protein (CRP) levels. Therefore, CRP may not serve as a dependable indicator for monitoring disease activity while undergoing TCZ treatment [<span>3</span>].</p><p>Serum amyloid A (SAA) and serum calgranulin C (S100A12) serve as reliable indicators of both local and systemic inflammation due to its production by inflammation-involved cells and has a systematic spill. It is a more dependable indicator than CRP or ESR for tracking disease progression in different rheumatic and autoinflammatory conditions, such as JIA, particularly in the age of biologic immunosuppressive treatment [<span>4, 5</span>].</p><p>The utilization of MSUS has proven to be a valuable method in assessing p-JIA. It allows for the visualization of inflammatory lesions prior to permanent joint damage, in addition to the monitoring of disease progression as well as treatment outcomes [<span>6</span>].</p><p>The objective of this study was to determine the significance of serum markers (amyloid A and calgranulin C) and musculoskeletal ultrasound in assessing disease activity in polyarticular JIA cases who are undergoing TCZ therapy.</p><p>This study involved 100 patients diagnosed with polyarticular JIA (p-JIA) based on the International League of Associations for Rheumatology (ILAR) [<span>1</span>] criteria for JIA. Subjects were categorized into two groups according to the line of treatment for 3 months (Group I: 50 patients with p-JIA on TCZ therapy; Group II: 50 patients with p-JIA on conventional DMARDS [c-DMARDS]). Additionally, 50 apparently healthy age and sex-matched children served as controls. Patients were recruited from the Rheumatology Department's Outpatient Clinic at Tanta University Hospitals. Exclusion criteria were other types of JIA, other biological therapy, infection, and malignancy. All participants provided informed consent, and the study received approval from the Local Research Ethical Committee, Faculty of Medicine, Tanta University (approval code No: 34276/11/20).</p><p>Patients underwent the following: (1) Disease activity evaluation, using JADAS 27 [<span>7</span>]. (2) Laboratory investigations i","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Importance of Image in Diagnosing Axial Involvement of Calcium Pyrophosphate Crystals Deposition Disease","authors":"Maria Pontes Ferreira, Patrícia Araújo, José Tavares-Costa, Diogo Roriz","doi":"10.1111/1756-185X.70012","DOIUrl":"10.1111/1756-185X.70012","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JIA, Today and Tomorrow","authors":"Wenbo Zhang, Huihua Yuan, Xing Lv, Chunlin Huang, Haisheng Zeng, Dexin Liu, Nicola Ruperto, Huasong Zeng","doi":"10.1111/1756-185X.70002","DOIUrl":"10.1111/1756-185X.70002","url":null,"abstract":"<p>Unexplained arthritis with symptoms lasting more than 6 weeks and onset before the age of 16 is categorized as juvenile idiopathic arthritis (JIA). This condition is the most prevalent chronic inflammatory rheumatic disease affecting children [<span>1</span>]. The seven different categories of JIA defined by the International League Against Rheumatism (ILAR) are based on the symptoms and signs that emerge in the first 6 months of disease. Although the prognosis of JIA has improved significantly, some children continue to experience inadequate responses to treatment. JIA has an impact on every aspect of the lives of children and their families, prompting researchers to focus on enhancing the health-related quality of life for those impacted by the condition. In this editorial, we focus on some new insights in the field of JIA treatment. Studies carried out by the Pediatric Rheumatology International Trials Organization (PRINTO) have enrolled more than 45 000 patients across 70 countries in 300 hospitals. This high number of cases demonstrates the significant increase in the clinical trials that have been completed since 2000 [<span>2</span>]. These trials do offer various different options for treating JIA. In particular, the final innovation is somewhat linked to Janus kinase (JAK) inhibitors [<span>3</span>].</p><p>In 2022, the American College of Rheumatology published its latest JIA guidelines. The escalation strategies for the three JIA phenotypes are as follows: (1) systemic JIA with and without macrophage activation syndrome (MAS), (2) oligoarthritis, and (3) temporomandibular joint (TML) arthritis [<span>4</span>]. A step-up strategy is considered to be the traditional JIA therapeutic approach. According to this method, the drug level is increased from first-line nonsteroidal anti-inflammatory drugs (NSAIDs) to conventional second-line synthetic disease-modifying antirheumatic drugs (cDMARDs), to progression biologic DMARDs (bDMARDs). This strategy is used to treat the various functional forms of JIA, including arthritis with fever (systemic JIA), JIA involving four or fewer joints (JIA with oligoarticular involvement), and JIA involving five or more joints (polyarticular course JIA) [<span>1</span>].</p><p>Articular injection of glucocorticoids is the gold standard of treatment for oligoarthritis. Scheduled NSAID is recommended as part of the initial therapy for active disease. bDMARDs are introduced for polyarticular course JIA, including anti-IL-6, anti-CTLA4, anti-TNF, and JAK inhibitors. These treatments are used when methotrexate fails to achieve disease remission, thereby significantly altering JIA treatment. NSAIDs and systemic glucocorticoids have long dominated treatment of systemic JIA; however, the current bDMARDs (IL-1 and IL-6 inhibitors) are conditionally recommended as the first monotherapy for systemic JIA in the absence of MAS [<span>1</span>]. IL-1 and IL-6 inhibitors have been rapidly adopted in clinical practice due","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: A Young Woman Diagnosed With Overlap Syndrome of Systemic Sclerosis and Ankylosing Spondylitis","authors":"Chen Li,&nbsp;Di Jin,&nbsp;Yu-Fang Gong,&nbsp;Hong-Xu Liu,&nbsp;Yi-Wei Guan,&nbsp;Sheng-Guang Li","doi":"10.1111/1756-185X.15427","DOIUrl":"10.1111/1756-185X.15427","url":null,"abstract":"<div>\u0000 \u0000 <p>This case report describes a rare occurrence of a 25-year-old female diagnosed with both systemic sclerosis (SSc) and ankylosing spondylitis (AS), two distinct autoimmune diseases. The patient presented with a combination of symptoms, including progressive skin tightening, lumbosacral pain, and Raynaud's phenomenon, which complicated the diagnosis. Despite the challenges posed by the coexistence of SSc and AS, a multidisciplinary treatment approach involving corticosteroids, immunosuppressants, and supportive therapies led to significant clinical improvement. Over the course of 3 weeks, the patient's Rodnan Skin Score improved from 18 to 11, and her pain and overall disease activity were markedly reduced. Although skin sclerosis showed substantial improvement, pulmonary involvement remains a concern that requires long-term monitoring. This case highlights the complexities in diagnosing and managing overlap syndromes, emphasizing the need for personalized treatment strategies and further investigation into the underlying genetic and immunological mechanisms.</p>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab for Induction Therapy of ANCA-Associated Vasculitis: Practical Issues in the Asia Pacific Region","authors":"Cheuk Man Ho,&nbsp;Chi Chiu Mok","doi":"10.1111/1756-185X.70016","DOIUrl":"10.1111/1756-185X.70016","url":null,"abstract":"&lt;p&gt;ANCA-associated vasculitis (AAV), comprising granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), represents a group of small to medium vessel vasculitides that may affect multiple organ systems, leading to vascular-mediated damage, organ failure, and mortality. Untreated AAV patients have a 1-year mortality of up to 80% [&lt;span&gt;1&lt;/span&gt;]. The introduction of glucocorticoids (GCs) and cyclophosphamide (CYC) as induction therapy in the 1960s has significantly improved the prognosis [&lt;span&gt;2&lt;/span&gt;]. In the landmark CYCLOPS trial published in 2009, the mortality of AAV patients treated with GCs and CYC at month 18 was 9% [&lt;span&gt;3&lt;/span&gt;]. From 1995 to 2012, the European Vasculitis Society (EUVAS) conducted seven randomized controlled trials (RCTs) to evaluate the efficacy of various induction therapies in AAV, including CYC, rituximab, mycophenolate mofetil, methotrexate, azathioprine, plasmapheresis, and pulse methylprednisolone. Pooled data from 848 patients in these studies revealed an overall survival rate of 88.2% at 1 year and 78.2% at 5 years from the time of diagnosis. Compared to the general population, excess mortality by 14% at 1 year and 20% at 10 years was observed, with infections, cardiovascular complications, and malignancies being the major causes of death [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;AAV exhibits notable variations in clinical manifestations between the Asian and Caucasian populations. Data from the Diagnostic and Classification Criteria in Vasculitis (DCVAS) group highlight a significantly higher proportion of anti-MPO-positive patients in the Japanese and Chinese compared to Northern Europeans (81.3% vs. 45.4% vs. 24.6%, respectively) [&lt;span&gt;5&lt;/span&gt;]. Apart from the anti-MPO predominance, Asian patients are also more likely to be classified as having MPA. A collaborative epidemiological study conducted simultaneously in Japan and the United Kingdom reported a much higher incidence of MPA in Japan (annual incidence per millions of adults: 18.2 vs. 6.5 in Japan and UK, respectively) despite a similar incidence of all subtypes of AAV [&lt;span&gt;6&lt;/span&gt;]. Asian AAV patients have less otorhinolaryngologic and ophthalmic involvement but more renal disease [&lt;span&gt;5&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;A difference in mortality was also observed between Asian and Caucasian patients with AAV according to real-world data. A recent study reported a high standardized mortality ratio (SMR) of MPA and GPA patients in South Korea (5.58 and 3.53, respectively) [&lt;span&gt;7&lt;/span&gt;]. The all-cause-mortality risk of MPA was higher than the GPA group after adjustment for age, sex, and comorbidities (HR 1.33, &lt;i&gt;p&lt;/i&gt; = 0.009). The SMR in this study is much higher than those reported in the Caucasians which range from 1.8 to 2.84 [&lt;span&gt;8-10&lt;/span&gt;]. The inter-ethnic differences in clinical manifestations, treatment response, and prognosis of AAV emphasize the need for personalized approach in the manage","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden of Diseases Dataset, Methodology and Its Use in Rheumatic and Musculoskeletal Diseases","authors":"Shi-Hang Chen,&nbsp;Yuan Tang,&nbsp;Harry Asena Musonye,&nbsp;Hai-Feng Pan","doi":"10.1111/1756-185X.15439","DOIUrl":"10.1111/1756-185X.15439","url":null,"abstract":"&lt;p&gt;The Global Burden of Disease (GBD) study has strictly adhered to the Guidelines for Accurate and Transparent Health Estimates Reporting [&lt;span&gt;1, 2&lt;/span&gt;], which aims to assess global mortality and disability rates caused by major diseases, injuries, and risk factors [&lt;span&gt;3&lt;/span&gt;]. Established in 1991, the study published its first results in 1993 [&lt;span&gt;4&lt;/span&gt;]. The most recent update, released in May 2024, provided data spanning 1990 to 2021. With nearly 12 000 researchers from 163 countries and territories involved, [&lt;span&gt;5&lt;/span&gt;] it has become the largest and most detailed scientific project to quantify health levels and trends worldwide [&lt;span&gt;3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;The GBD study comprehensively evaluated various causes of death, injuries, risk factors, and health conditions, providing a critical basis for analyzing global population health and trends [&lt;span&gt;2, 6-9&lt;/span&gt;]. It also helped the health sector identify overlooked health issues, reveal inequalities, predict dynamic trends, and guide policy formulation.&lt;/p&gt;&lt;p&gt;The GBD study covered 204 countries and territories, divided into 7 super-regions, 21 regions, and multiple custom regions, with one widely used being a five-level classification based on the Sociodemographic Index (SDI). The SDI, [&lt;span&gt;6, 7&lt;/span&gt;] a geometric mean of the total fertility rate under age 25, mean years of education for those aged 15 and older, and lag-distributed income per capita, ranged from 0 to 1. It is divided into five categories: 0–0.47 for low SDI, 0.47–0.62 for low-middle SDI, 0.62–072 for middle SDI, 0.72–0.81 for high-middle SDI, and 0.81–1.00 for high SDI [&lt;span&gt;10&lt;/span&gt;]. In addition, subnational analyses were conducted in 21 countries [&lt;span&gt;6, 7&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;A key feature of the GBD study was detailed age stratification, covering 51 age groups from birth to 95 years and older [&lt;span&gt;8&lt;/span&gt;]. Age-standardized rates (ASRs) [&lt;span&gt;11&lt;/span&gt;] were used to remove the influence of differing age structures between populations, ensuring more accurate comparisons of disease or mortality rates across populations.&lt;/p&gt;&lt;p&gt;The GBD study's data was sourced from hospitals, government agencies, surveys, and other databases worldwide. The Global Health Data Exchange (GHDx) platform [&lt;span&gt;12&lt;/span&gt;] provided a directory of the GBD study input data sources. A detailed methodological information for various diseases, injuries, and risk factors can be found in GBD 2021 Methods Appendices (Table 1) [&lt;span&gt;13&lt;/span&gt;]. A principle of GBD study was the comparability of research results. To achieve this, the GBD study employed a series of methods during data processing, including quality rating of studies, independent disease coding, and standardized data modeling analysis, to enhance consistency and comparability across different countries and data sources.&lt;/p&gt;&lt;p&gt;Data input methods for diseases and injuries were categorized into causes of deaths [&lt;span&gt;7&lt;/span&gt;] and nonfatal health outcomes [&lt;span&gt;6&lt;/span&gt;]. ","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.15439","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential Role of Neutrophil Reactivity Intensity and Reactive Lymphocytes as Extended Hematological Parameters to Detect Active Systemic Lupus Erythematosus","authors":"Andri Iskandar Mardia,&nbsp;Laniyati Hamijoyo,&nbsp;Evan Susandi,&nbsp;Delita Prihatni,&nbsp;Bachti Alisjahbana,&nbsp;Amaylia Oehadian","doi":"10.1111/1756-185X.15449","DOIUrl":"10.1111/1756-185X.15449","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of autoantibodies against nuclear antigens and immune complex deposition. The pathogenesis of SLE is not fully understood; however, there are alterations in neutrophils and lymphocytes. Recent parameters assessing both neutrophil activations (Neut-RI, Neut-GI, IG) and activated lymphocytes (Re-Lymp, As-Lymp) can be used to assess the activation of immune cells. The aim of this study was to explore the potential role of this parameter in detecting active SLE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cross-sectional study using secondary data from Hasan Sadikin Lupus Registry. Parameters were examined using Sysmex XN-1500. Lupus activity was determined according to SLEDAI-2K.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This study included 30 active (SLEDAI 2K ≥ 4) and 30 inactive SLE patients. Compared to inactive SLE, active SLE showed significantly higher Neut-RI (51.5 vs. 49.6 FL, <i>p</i> = 0.004), and lower Re-Lymph (0.09 vs. 0.14 × 10³/mm³, <i>p</i> = 0.024). There was no significant difference in Neut-GI (150 vs. 151.6 SI, <i>p</i> = 0.359), As-Lymp (0.02 vs. 0.01 × 10³/mm³, <i>p</i> = 0.621), and IG (0.11 vs. 0.06 × 10³/mm³, <i>p</i> = 0.384) between active and inactive SLE. Neut-RI/Re-Lymp ratio cutoff &gt; 0.47 could distinguish between active and inactive SLE with AUC 0.689, 66.7% sensitivity, and 70.0% specificity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In active SLE, there is an elevation in Neut-RI and a reduction in Re-Lymp. Neut-RI/Re-Lymp ratio exceeding 0.47 could be used to detect active SLE.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alterations on Nailfold Videocapillaroscopy in Myelodysplastic Syndrome and Onychomycosis in a Female Smoker: Microvascular Dysfunction Without Connective Tissue Disease","authors":"Angelo Nigro","doi":"10.1111/1756-185X.70000","DOIUrl":"10.1111/1756-185X.70000","url":null,"abstract":"<div>\u0000 \u0000 <p>A 58-year-old female smoker diagnosed with myelodysplastic syndrome (MDS) presented with Raynaud's phenomenon and a “scleroderma-like” pattern on nailfold capillaroscopy. The capillaroscopic abnormalities were observed across all fingers, including those without clinical manifestations of onychomycosis. Over a two-year follow-up, there was no evidence of clinical or serological progression toward a connective tissue disease, particularly systemic sclerosis. This case underscores the potential contributory role of MDS and smoking in the development of microvascular dysfunction, presenting as capillaroscopic abnormalities in the absence of an underlying autoimmune disorder.</p>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 Vaccination in Patients With Systemic Lupus Erythematosus: Adverse Events and Rating Agreement of Flares Between Patients and Physicians","authors":"Punsita Tangkum,&nbsp;Nuntana Kasitanon,&nbsp;Wanitcha Gumtorntip,&nbsp;Poramed Winichakoon,&nbsp;Supparat Konsamun,&nbsp;Antika Wongthanee,&nbsp;Worawit Louthrenoo","doi":"10.1111/1756-185X.70001","DOIUrl":"10.1111/1756-185X.70001","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To compare adverse events and flares among different doses and types of COVID-19 vaccines in patients with systemic lupus erythematosus (SLE).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>All consecutive SLE patients in a lupus cohort, seen between March and October 2022, were invited to join this retrospective study. Inclusion criteria were aged ≥ 20 years and had received at least one dose of COVID-19 vaccine. Data regarding adverse events after vaccination, clinical disease activity and flares within 30 days postvaccination were reviewed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 201 SLE patients received 524 vaccine doses, with 201, 199, and 124 patients received 1, 2, and 3 doses, respectively. The vaccines included inactivated virus vaccine, adenovirus-vectored vaccine, and mRNA vaccines in 183 (35%), 128 (24%), and 213 (41%) doses, respectively. Regardless of the dose and type of vaccine, adverse events occurred in 50%–70% of patients. Pain and swelling at the injection site were common local symptoms, whereas constitutional, neurological, musculoskeletal, and mucocutaneous symptoms were among systemic ones. The majority of these symptoms were mild to moderate. Patients reported they had disease flares after vaccination in 5%–6%, while actual flares determined by physicians occurred in 8%–13% of them, giving fair to moderate rating agreement between patients and physicians (Cohen's kappa: 0.21–0.44). There was no significant difference in mean mSLEDAI-2K between pre- and 30 days postvaccination.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Adverse events after vaccination were common, regardless of the dose or type of COVID-19 vaccines, but only a small proportion of patients had severe symptoms. Flares were uncommon. The rating agreement of flares between patients and physicians as fair to moderate.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “SAPHO Syndrome With Refractory Mandibular Osteitis”","authors":"","doi":"10.1111/1756-185X.70010","DOIUrl":"10.1111/1756-185X.70010","url":null,"abstract":"<p>Mori Y, Izumiyama T, Kanabuchi R, Mori N, Aizawa T. SAPHO Syndrome With Refractory Mandibular Osteitis. <i>International Journal of Rheumatic Diseases</i> 2024;27:e15059.</p><p>The second reference in the above article has been amended to: “Mori Y, Izumiyama T, Okuno H, et al. Assessment of clinical and radiological characteristics of Japanese patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. <i>Mod Rheumatol</i>. 2023. https://doi.org/10.1093/mr/road086”.</p><p>The online article has been amended.</p><p>We apologize for this error.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}